Cytomegalovirus (CMV) Reactivation in Allogeneic HSCT Recipient

Cytomegalovirus Infections Clinical Trial

— CReSCT  

Official title:

Assessing the Impact and Complications of Cytomegalovirus (CMV) Reactivation in a Multi-site Study of Allogeneic Haematopoietic Stem Cell Transplant Recipient

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT03806764
• Other study ID #: CReSCT
• Status: Enrolling by invitation
• Phase: N/A
• Start date: April 17, 2018
• Est. completion date: December 31, 2023

Study information

• Verified date: May 2023
• Source: Melbourne Health
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study consists of two parts: 1) Part 1, a retrospective part on 250 consecutive patients following allogeneic haematopoietic stem cell transplant (allo-HSCT) at the Royal Melbourne Hospital from 2012 to 2017, inclusive, and 2) Part 2, a prospective part on 120 allo-HSCT patients from 4 sites in Australia: the Royal Melbourne Hospital, Peter MacCallum Cancer Centre, Austin Hospital, and Westmead Hospital. In Part 1, medical records of allo-HSCT recipients will be evaluated to determine the incidence and clinical outcomes of CMV viremia post HSCT, including both the direct (CMV disease) and indirect (such as invasive fungal infection, other viral infections, bacterial infection) effects on clinical outcomes. In Part 2, allo-HSCT participants at risk of CMV disease will be assessed to determine the association of host CMV-specific immunity with clinical management and outcomes over one year post allo-HSCT. The overall aims of the study are to establish if CMV infection in allo-HSCT patients are associated with poor clinical outcomes; and whether measurement of immunological functions could provide an early indicator to identify patients at risk and appropriate timing for initiation of CMV treatment.

Description:

Cytomegalovirus (CMV) infection is recognised as one of the most common and important infectious complication of allogeneic haematopoietic stem cell transplantation (allo-HSCT). Despite the serious clinical implications of CMV reactivation, there is a paucity of data informing clinicians on how to best identify 'at risk' patients, timely commencement of management of the infection. This study consists of two parts: 1) Part 1, a retrospective part, and 2) Part 2, a prospective part. In Part 1, a retrospective cohort of 250 recipients of allo-HSCT at the Royal Melbourne Hospital will be reviewed. The study period will be between January 2012- December 2017, inclusive. The follow up period will be 6 months from the day of transplantation (ie. day 0 to 180). Data on patient demographics (age, sex, ethnicity), primary indication for transplantation, donor type (match, unmatched, minor mismatch, related or unrelated), graft source (stem cell, bone marrow, umbilical cord) conditioning regimen (myeloablative reduced intensity conditioning), graft versus host disease (GVHD) prophylaxis eg. T-cell depletion, days to neutrophil recovery, occurrence of acute and chronic GVHD and the therapy for GVHD (including steroid intensity, use of ATG etc.), associated bacterial and fungal infections, relapse and mortality, will be collected for analyses. CMV-negative patients will be used as control for economic comparisons. In Part 2, 120 recipients of allo-HSCT will be recruited from 4 Australian hospitals (the Royal Melbourne Hospital, Austin Hospital, Peter MacCallum Cancer Centre, and Westmead Hospital). Participants will be reviewed pre-transplant, 6, 12, 24 and 52 weeks following HSCT during routine clinical visits. Clinical assessment will be made such as CMV viremia, transplant related complications and current medications. In addition, participants who are at high risk of CMV will have study bloods taken to assess immune functions with Quantiferon-CMV®, Quantiferon-Monitor® assay, CMV Elispot, peripheral blood mononuclear cells (PBMCs) and plasma for storage at time-points of 0, 6 and 12 weeks +/- 2 weeks after commencing anti-CMV treatment. The Quantiferon-Monitor® assay will be performed at the additional time points of 4, 18 and 26 weeks following HSCT.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 370
• Est. completion date: December 31, 2023
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• For the retrospective cohort, all 250 consecutive allo-HSCT patients between 2012 to 2017 at the Royal Melbourne Hospital will be included, with CMV-negative patients acting as controls for economic comparisons.
• For the prospective cohort, patients undergoing allo-HSCT, at risk of CMV disease (D+/R+, D-/R+ D+/R-), and able to provide informed consent.

Exclusion Criteria:

• For the retrospective cohort, no exclusion is set.
• For the prospective cohort, patients who has CMV disease at the time of enrolment and patients who are unable to provide informed consent.

Related Conditions & MeSH terms

• Cytomegalovirus Infections
• Haematological Malignancy
• Hematologic Neoplasms
• Immune Suppression
• Organ or Tissue Transplant; Complications

Intervention

Diagnostic Test:
• Blood sampling
Blood sampling from prospective study participants will be taken for immune functions measurements

Locations

Country	Name	City	State
Australia	Royal Melbourne Hospital	Parkville	Victoria

Sponsors (5)

Lead Sponsor	Collaborator
Melbourne Health	Austin Hospital, Melbourne Australia, Peter MacCallum Cancer Centre, Australia, Walter and Eliza Hall Institute of Medical Research, Western Sydney Local Health District

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence and outcome of CMV viremia	The incidence and outcome of clinically relevant CMV viremia post HSCT will be assessed	250 retrospective cases of HSCTduring 2012 to 2017, inclusive, will be reviewed from the day of transplant to 6 months post transplant.
Primary	Host CMV-specific T cell immunity and related clinical outcomes	Host CMV-specific T cell immunity status of 120 participants will be assessed prospectively against CMV related clinical outcomes to establish if correlations exist	52 weeks following HSCT
Secondary	Low level CMV viremia	Association of low level CMV viremia and the subsequent clinical outcomes	250 retrospective cases of HSCTduring 2012 to 2017, inclusive, will be reviewed from the day of transplant to 6 months post transplant.
Secondary	Economic cost for managing CMV infection	The economic cost attributable to managing CMV infection and CMV disease will be evaluated to provide a picture of health economics of the infection	250 retrospective cases of HSCTduring 2012 to 2017, inclusive, will be reviewed from the day of transplant to 6 months post transplant.
Secondary	CMV viral load for initiation of treatment	CMV viral load will be assessed to determine an appropriate trigger to initiate treatment for CMV viremia	52 weeks following HSCT
Secondary	Correlation of host T cell function and risk of CMV infection	Association of low or inadequate global immune function (T-cell and TLR7 responses) will be correlated with an increased risk of developing CMV infection post HSCT	52 weeks following HSCT